Cargando…

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland

AIM OF THE STUDY: The first aim was to investigate the knowledge and awareness of oncologists concerning febrile neutropenia (FN) risk assessment and indications for granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP), based on current therapeutic guidelines (PTOK and EORTC). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojtukiewicz, Marek, Chmielowska, Ewa, Filipczyk-Cisarż, Emilia, Krzemieniecki, Krzysztof, Leśniewski-Kmak, Krzysztof, Litwiniuk, Maria M., Wieruszewska-Kowalczyk, Karolina, Kosno-Kruszewska, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355659/
https://www.ncbi.nlm.nih.gov/pubmed/25784841
http://dx.doi.org/10.5114/wo.2014.47904
_version_ 1782360897628405760
author Wojtukiewicz, Marek
Chmielowska, Ewa
Filipczyk-Cisarż, Emilia
Krzemieniecki, Krzysztof
Leśniewski-Kmak, Krzysztof
Litwiniuk, Maria M.
Wieruszewska-Kowalczyk, Karolina
Kosno-Kruszewska, Elżbieta
author_facet Wojtukiewicz, Marek
Chmielowska, Ewa
Filipczyk-Cisarż, Emilia
Krzemieniecki, Krzysztof
Leśniewski-Kmak, Krzysztof
Litwiniuk, Maria M.
Wieruszewska-Kowalczyk, Karolina
Kosno-Kruszewska, Elżbieta
author_sort Wojtukiewicz, Marek
collection PubMed
description AIM OF THE STUDY: The first aim was to investigate the knowledge and awareness of oncologists concerning febrile neutropenia (FN) risk assessment and indications for granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP), based on current therapeutic guidelines (PTOK and EORTC). The second aim was to educate the oncologists on best practices for risk assessment and neutropenia management. MATERIAL AND METHODS: The project participants included 169 oncologists from 7 regions working in large specialist oncological centres, university hospitals, regional and city hospitals, specialist outpatient clinics, and oncological wards in small local hospitals. The participants completed a questionnaire based on seven prepared clinical cases of patients with different tumour types and patient characteristics, receiving chemotherapy (CT), and with different levels of FN risk. Participants answered questions related to FN risk assessment and G-CSF use. After completing the questionnaire, the participants proceeded to an educational module in which they were provided with an analysis of correct diagnostic and therapeutic procedures according to the PTOK and EORTC guidelines. RESULTS AND CONCLUSIONS: Febrile neutropenia risk assessment was found to be a routine procedure performed for over 90% of the clinical cases by the participant oncologists. However, the FN risk assessment of clinical cases was correct and consistent with therapeutic guidelines in only 65% of responses. Indications for G-CSF PP were properly identified in 76% of responses and it appeared that indications for G-CSF PP were more likely to be correctly identified in patients receiving high-risk or low-risk regimens than in those receiving intermediate-risk regimens, where the decision to give G-CSF PP is based on additional assessment of patient risk factors. The vast majority of participants who correctly identified the need for PP administered G-CSF in accordance with the dose and schedule recommended by PTOK and EORTC.
format Online
Article
Text
id pubmed-4355659
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-43556592015-03-17 Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland Wojtukiewicz, Marek Chmielowska, Ewa Filipczyk-Cisarż, Emilia Krzemieniecki, Krzysztof Leśniewski-Kmak, Krzysztof Litwiniuk, Maria M. Wieruszewska-Kowalczyk, Karolina Kosno-Kruszewska, Elżbieta Contemp Oncol (Pozn) Original Paper AIM OF THE STUDY: The first aim was to investigate the knowledge and awareness of oncologists concerning febrile neutropenia (FN) risk assessment and indications for granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP), based on current therapeutic guidelines (PTOK and EORTC). The second aim was to educate the oncologists on best practices for risk assessment and neutropenia management. MATERIAL AND METHODS: The project participants included 169 oncologists from 7 regions working in large specialist oncological centres, university hospitals, regional and city hospitals, specialist outpatient clinics, and oncological wards in small local hospitals. The participants completed a questionnaire based on seven prepared clinical cases of patients with different tumour types and patient characteristics, receiving chemotherapy (CT), and with different levels of FN risk. Participants answered questions related to FN risk assessment and G-CSF use. After completing the questionnaire, the participants proceeded to an educational module in which they were provided with an analysis of correct diagnostic and therapeutic procedures according to the PTOK and EORTC guidelines. RESULTS AND CONCLUSIONS: Febrile neutropenia risk assessment was found to be a routine procedure performed for over 90% of the clinical cases by the participant oncologists. However, the FN risk assessment of clinical cases was correct and consistent with therapeutic guidelines in only 65% of responses. Indications for G-CSF PP were properly identified in 76% of responses and it appeared that indications for G-CSF PP were more likely to be correctly identified in patients receiving high-risk or low-risk regimens than in those receiving intermediate-risk regimens, where the decision to give G-CSF PP is based on additional assessment of patient risk factors. The vast majority of participants who correctly identified the need for PP administered G-CSF in accordance with the dose and schedule recommended by PTOK and EORTC. Termedia Publishing House 2014-12-31 2014 /pmc/articles/PMC4355659/ /pubmed/25784841 http://dx.doi.org/10.5114/wo.2014.47904 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Wojtukiewicz, Marek
Chmielowska, Ewa
Filipczyk-Cisarż, Emilia
Krzemieniecki, Krzysztof
Leśniewski-Kmak, Krzysztof
Litwiniuk, Maria M.
Wieruszewska-Kowalczyk, Karolina
Kosno-Kruszewska, Elżbieta
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
title Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
title_full Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
title_fullStr Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
title_full_unstemmed Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
title_short Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
title_sort clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in poland
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355659/
https://www.ncbi.nlm.nih.gov/pubmed/25784841
http://dx.doi.org/10.5114/wo.2014.47904
work_keys_str_mv AT wojtukiewiczmarek clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT chmielowskaewa clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT filipczykcisarzemilia clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT krzemienieckikrzysztof clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT lesniewskikmakkrzysztof clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT litwiniukmariam clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT wieruszewskakowalczykkarolina clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland
AT kosnokruszewskaelzbieta clinicalpracticeinfebrileneutropeniariskassessmentandgranulocytecolonystimulatingfactorprimaryprophylaxisoffebrileneutropeniainpoland